Cash and cash equivalents were $33.5M as of June 30. “Our strong commercial performance was driven by the continued adoption of our highly differentiated AI-enabled aprevo technology platform and growing recognition of its ability to deliver more favorable patient outcomes than legacy devices,” said Mike Cordonnier, chairman and CEO of Carlsmed (CARL). “Building upon our momentum in personalized lumbar fusion surgery, in July we successfully completed the first personalized cervical spine surgery using our aprevo(R) technology platform, launching in 2026. We enter the second half of 2025 well positioned for continued scale as we become the new standard of care in spine fusion surgery.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARL:
- CVS Health upgraded, Occidental downgraded: Wall Street’s top analyst calls
- Carlsmed initiated with a Buy at Truist
- Buy Rating for Carlsmed: Innovative Aprevo Technology and Strong Growth Projections Justify Premium Valuation
- Carlsmed initiated with a Buy at BofA
- Carlsmed initiated with a Buy at BTIG